In premenopausal patients, chemotherapy's observed benefit may be an indirect effect of inducing menopause, rather than its cell-killing properties. The ongoing OFFSET trial is testing if optimizing endocrine therapy with ovarian suppression can achieve the same risk reduction as chemotherapy, potentially avoiding chemo's side effects entirely for this group.
The TRAIL trial found starting abemaciclib at a low dose (50mg) and escalating every two weeks drastically improves tolerability. This approach reduced Grade 3 diarrhea from 7.8% in the pivotal trial to just 3.3% and lowered early discontinuation rates, allowing more patients to reach the full therapeutic dose and stay on treatment.
Trials like TaylorX and MINDACT use genomic scores to identify patients with early-stage, HR+/HER2- breast cancer who won't benefit from adjuvant chemotherapy. This avoids significant toxicity for two-thirds to over 80% of patients who would have received it under older guidelines, without compromising their outcomes.
The KEYNOTE-756 and Checkmate 7FL trials found high pathological complete response (pCR) rates with neoadjuvant immunotherapy in ER-low (1-10%) breast cancers. This suggests this unique subgroup, often excluded from triple-negative trials but behaving similarly, may benefit significantly from immunotherapy, though it is not yet standard of care.
When choosing an adjuvant CDK4/6 inhibitor for high-risk HR+ breast cancer, clinicians favor abemaciclib. The key deciding factors are its proven overall survival (OS) benefit from the MonarchE trial and a more appealing two-year treatment course, compared to ribociclib's three-year duration and not-yet-mature OS data.
Contrary to the belief that HR+ breast cancer primarily carries a late recurrence risk, data shows high-risk, node-positive patients can be extremely aggressive early on. With recurrence rates up to 29.1% within five years, this subgroup can perform as poorly, or even worse, than triple-negative breast cancer, highlighting the need for intensive adjuvant therapy.